Humacyte Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
184
- Stock Symbol
-
HUMA
- Investments
-
2
- Share Price
-
$0.45
- (As of Friday Closing)
Humacyte General Information
Description
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Contact Information
Website
www.humacyte.comCorporate Office
- 2525 East Highway North Carolina 54
- Durham, NC 27713
- United States
Corporate Office
- 2525 East Highway North Carolina 54
- Durham, NC 27713
- United States
Humacyte Timeline
Humacyte Stock Performance
As of 20-Nov-2026, Humacyte’s stock price is $0.45. Its current market cap is $124M with 278M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.45 | $0.54 | $0.34 - $1.52 | $124M | 278M | 5.42M | -$0.45 |
Humacyte Financials Summary
As of 30-Sep-2026, Humacyte has a trailing 12-month revenue of $2.4M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 130,093 | 195,710 | 646,472 | 213,661 |
| Revenue | 2,396 | 2,038 | 0 | 0 |
| EBITDA | (79,441) | (24,825) | (136,338) | (103,944) |
| Net Income | (94,763) | (40,833) | (148,701) | (110,776) |
| Total Assets | 125,572 | 116,366 | 137,872 | 128,223 |
| Total Debt | 66,482 | 64,846 | 16,537 | 18,853 |
Humacyte Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Humacyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Humacyte Comparisons
Industry
Financing
Details
Humacyte Competitors (51)
One of Humacyte’s 51 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Sernova Biotherapeutics | Corporation | Mississauga, Canada | ||||
| Orgenesis | Corporation | Germantown, MD | ||||
| Orbsen Therapeutics | Formerly PE-Backed | Galway, Ireland | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA |
Humacyte Patents
Humacyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024207955-A1 | Devices and methods of a medicament-producing implantable matrix | Pending | 11-Jan-2023 | ||
| EP-4648748-A2 | Devices and methods of a medicament-producing implantable matrix | Pending | 11-Jan-2023 | ||
| US-20260216406-A1 | Devices and methods of a medicament-producing implantable matrix | Pending | 11-Jan-2023 | ||
| WO-2024151852-A2 | Devices and methods of a medicament-producing implantable matrix | Inactive | 11-Jan-2023 | ||
| WO-2024151852-A3 | Devices and methods of a medicament-producing implantable matrix | Inactive | 11-Jan-2023 | A61K9/0024 |
Humacyte Signals
Humacyte Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Humacyte Acquisitions (2)
Humacyte’s most recent deal was a Merger/Acquisition with Alpha Healthcare Acquisition. The deal was made on 26-Aug-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Alpha Healthcare Acquisition | 26-Aug-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Biopharma Excellence | 01-Jun-2021 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Humacyte ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.74 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Humacyte Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Biopharma Excellence | Friedrichsdorf, Germany | 2013 |
Humacyte FAQs
-
When was Humacyte founded?
Humacyte was founded in 2004.
-
Where is Humacyte headquartered?
Humacyte is headquartered in Durham, NC.
-
What is the size of Humacyte?
Humacyte has 184 total employees.
-
What industry is Humacyte in?
Humacyte’s primary industry is Biotechnology.
-
Is Humacyte a private or public company?
Humacyte is a Public company.
-
What is Humacyte’s stock symbol?
The ticker symbol for Humacyte is HUMA.
-
What is the current stock price of Humacyte?
As of 20-Nov-2026 the stock price of Humacyte is $0.45.
-
What is the current market cap of Humacyte?
The current market capitalization of Humacyte is $124M.
-
What is Humacyte’s current revenue?
The trailing twelve month revenue for Humacyte is $2.4M.
-
Who are Humacyte’s competitors?
Centrose, Sernova Biotherapeutics, Orgenesis, Orbsen Therapeutics, and Sangamo Therapeutics are some of the 51 competitors of Humacyte.
-
What is Humacyte’s annual earnings per share (EPS)?
Humacyte’s EPS for 12 months was -$0.45.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process